ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Share Price vs Market Cap

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Jul 05, 2021 10:36am

98 Views

Post# 33492522

RE:RE:Share Price vs Market Cap

One of the biggest issues with PMN is the Dilution of Shares. 330 Million Shares. 1/3 of those Shares had Voted this past AGM. I believe once the Serology Test is complete there will be Revenue. There is no way the Boston Group and the newly elected Board Members (Respected in their fields) are sitting Idle while Biogens Aducanumab and Eli Lilly's Drug are Approved. If PMN is the Best In Class, then its time to clean up the Shares. Otherwise great time to Buy and Hold!

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages